产品
编 号：F259312
分子式：C7H13F2NO2
分子量：181.18
分子式：C7H13F2NO2
分子量：181.18
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 2095886-80-7
产品详情
生物活性：
NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 is used for antidepressant studies.
体内研究：
NV-5138 is found to be essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h determined following intravenous and oral dosing in rats.NV-5138 (160 mg/kg, po, single dose) rapidly increases levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phosphor-4EB-P1, in synaptosomal preparations of PFC.NV-5138 (80 mg/kg, po, daily for a total of 7 days) also produces antidepressant effects.Animal Model:Male Sprague-Dawley rats weighing 250-260 g.
Dosage:40, 80, 160 mg/kg.
Administration:PO, single dose (160 mg/kg) or daily for a total of 7 days (40, 80 mg/kg).
Result:Produced antidepressant effects.
Animal Model:Male Sprague–Dawley (SD) rats weighed 250-400 g.
Dosage:1 mg/kg, 5 mg/kg (Pharmacokinetic Design).
Administration:I.V at 1 mg/kg and PO at 5 mg/kg.
Result:Essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h.
NV-5138, a leucine analog, is the first selective and orally active brain mTORC1 activator, binding to Sestrin2. NV-5138 is used for antidepressant studies.
体内研究：
NV-5138 is found to be essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h determined following intravenous and oral dosing in rats.NV-5138 (160 mg/kg, po, single dose) rapidly increases levels of phospho-mTOR as well as the downstream targets, phospho-p70S6K1, and phosphor-4EB-P1, in synaptosomal preparations of PFC.NV-5138 (80 mg/kg, po, daily for a total of 7 days) also produces antidepressant effects.Animal Model:Male Sprague-Dawley rats weighing 250-260 g.
Dosage:40, 80, 160 mg/kg.
Administration:PO, single dose (160 mg/kg) or daily for a total of 7 days (40, 80 mg/kg).
Result:Produced antidepressant effects.
Animal Model:Male Sprague–Dawley (SD) rats weighed 250-400 g.
Dosage:1 mg/kg, 5 mg/kg (Pharmacokinetic Design).
Administration:I.V at 1 mg/kg and PO at 5 mg/kg.
Result:Essentially 100% orally bioavailable with an elimination half-life in plasma of ~ 3 h.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备